# ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

> **NCT04579523** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **RADIATION:** Total-Body Irradiation
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT04579523
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04579523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04579523, "²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04579523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*